Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911396 | 0.83 | MAPT (0.42) | POLBDGAT1TP53MAPTALDH1A1 | |
| SCHEMBL9911393 | 0.79 | DGAT1 (0.44) | POLBDGAT1TP53MAPTGAA | |
| SCHEMBL861021 | 0.77 | POLB (0.41) | POLBTP53MAPTGAAALDH1A1 | |
| SCHEMBL861475 | 0.77 | POLB (0.44) | POLBTP53MAPTGAAALDH1A1 | |
| SCHEMBL861343 | 0.76 | POLB (0.42) | POLBTP53MAPTGAAALDH1A1 | |
| SCHEMBL861073 | 0.70 | SMN1; SMN2 (0.41) | POLBDGAT1TP53MAPTALDH1A1 | |
| SCHEMBL854534 | 0.69 | DGAT1 (0.42) | POLBDGAT1TP53MAPTALDH1A1 | |
| SCHEMBL861156 | 0.69 | KMT2A (0.43) | POLBDGAT1TP53MAPTGAA | |
| SCHEMBL9911395 | 0.68 | POLB (0.43) | POLBTP53MAPTGAAALDH1A1 | |
| SCHEMBL861557 | 0.66 | RAB9A (0.42) | POLBTP53MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2432468-A2 | METHODS OF MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | POLB 2508/4885DGAT1 1133/4885TP53 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.